不孕症治療藥物和醫療設備市場：按類型、性別和地區分類

Infertility Drugs and Devices Market, By Type, By Gender, and by Region

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，不孕症治療和醫療設備市場規模將達到91.5億美元，到2033年將達到142.2億美元。預計從2026年到2033年，該市場將以6.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	91.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.50%	2033年市場規模預測：	142.2億美元

不孕症藥物和醫療設備用於治療男性和女性不孕症。女性不孕症的主要原因包括子宮內膜異位症、卵巢疾病、子宮疾病、輸卵管疾病和荷爾蒙失衡等，而男性不孕症則由無精子症、精索靜脈曲張、射精功能障礙和勃起功能障礙引起。治療方案包括藥物治療、輔助生殖技術（ART）、手術、人工授精和體外受精。預計在預測期內，勃起功能障礙盛行率的上升、研發投入的活性化、新產品的核准以及市場主要參與者採取的擴大策略將推動市場成長。

市場動態

市場上的主要參與者正致力於透過合作策略拓展產品系列。例如，2020年5月，女性健康解決方案開發商Dare Bioscience, Inc.與Health Decisions, Inc.達成合作。 Health Decisions是一家提供全方位服務的合約研究組織（CRO），專注於女性健康相關的臨床研究和診斷開發。根據這項合作協議，Health Decisions將獨家為Dare在美國提供CRO服務，以支持其避孕、生育治療和婦科疾病相關產品的研發。此外，市場上的主要參與者也致力於推出學名藥學名藥以拓展產品系列。例如，2020年9月，總部位於孟買的跨國製藥公司Lupin Limited推出了25毫克、50毫克和100毫克劑量的Sildenafil片（USP），這是輝瑞公司威而鋼的學名藥。生育診所的開設也是推動市場成長的因素之一。例如，2021年9月，櫻花世界醫院開始提供不孕症治療，並為每位患者制定個人化的治療方案。預計這些因素將在不久的將來推動市場擴張。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，對全球不孕症治療和醫療設備市場的主要參與者進行了概況介紹：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
全球不孕症治療和醫療設備市場報告的目標受群眾外包括該行業的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球不孕症治療和醫療設備市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Apricus Biosciences, Inc.
- Bayer AG
- Cristalia Produtos Quimicos Farmaceuticos Ltda.
- Dong-A Pharmaceutical Co. Ltd.
- Eli Lilly and Company
- Meda Pharmaceuticals, Inc.
- Pfizer, Inc.
- SK Chemicals Co. Ltd.
- Vivus, Inc.
- Mylan Pharmaceuticals Inc.
- Ferring Pharmaceuticals
- Cipla Ltd
- Aspargo Laboratories, Inc.
- Aurobindo Pharma Ltd.
- Lupin Limited
- Novartis International AG
- DarA（C）Bioscience, Inc.
- Torrent Pharmaceuticals Ltd.
- Alembic Pharmaceuticals
- Reddys Laboratories Ltd.

第9章

參考
調查方法

簡介目錄

Product Code: CMI4122

Infertility Drugs And Devices Market is estimated to be valued at USD 9.15 Bn in 2026 and is expected to reach USD 14.22 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9.15 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.50%	2033 Value Projection:	USD 14.22 Bn

Infertility Drugs and Devices used for treating infertility in male and female. Factors such as endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction. Treatment procedure constitutes of drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination, and in vitro fertilization. Increasing prevalence of erectile dysfunction, increasing research & development, new product approval, and adoption of expansion strategies from major players operating in the market is expected to propel the market growth during the forecast period.

Market Dynamics

The key market players in the market are focused on adopting partnership strategies to expand its product portfolio. For instance, in May 2020, Dare Bioscience, Inc., a developer of women's health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women's health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Dare's pipeline of contraception, fertility, and gynecological disorders products. Moreover, Major players in the market are also focused on launching generic drugs to expand its product portfolio. For instance, in September 2020, Lupin Limited, a multinational pharmaceutical company based in Mumbai, launched Sildenafil tablets, USP of 25 mg, 50 mg, and 100 mg, a generic version of Pfizer Inc.'s Viagra tablets. Moreover, the launch of fertility clinics is another factor in the growth of the market. For instance, in September 2021, Sakra World Hospital began offering infertility treatments, creating personalized treatment regimens for each patient. Such factors would spur market expansion in the near future.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global infertility drugs and devices market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include include Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Dare Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global infertility drugs and devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global infertility drugs and devices market.

Detailed Segmentation:

Global Infertility Drugs and Devices Market, By Type (Revenue, USD Bn, 2021 - 2033)
Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
Infertility Devices
Equipment
Accessories
Global Infertility Drugs and Devices Market, By Gender (Revenue, USD Bn, 2021 - 2033)
Male
Female
Global Infertility Drugs and Devices Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Apricus Biosciences, Inc.
Bayer AG
Cristalia Produtos Quimicos Farmaceuticos Ltda.
Dong-A Pharmaceutical Co. Ltd.
Eli Lilly and Company
Meda Pharmaceuticals, Inc.
Pfizer, Inc.
S.K. Chemicals Co. Ltd.
Vivus, Inc.
Mylan Pharmaceuticals Inc.
Ferring Pharmaceuticals
Cipla Ltd
Aspargo Laboratories, Inc.
Aurobindo Pharma Ltd.
Lupin Limited
Novartis International AG
Dare Bioscience, Inc.
Torrent Pharmaceuticals Ltd.
Alembic Pharmaceuticals
Dr. Reddys Laboratories Ltd.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Gender
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
Key Developments
PEST Analysis
Economic Impact
Impact on Supply and Demand

5. Global Infertility Drugs and Devices Market, By Type, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Infertility Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
  - Clomiphene citrate
  - Sex hormones
  - Gonadotropins
  - Bromocriptine
  - Cabergoline
  - Imipramine
  - Letrozole
  - Metformin
Infertility Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Segment Trends
  - Equipment
  - Accessories

6. Global Infertility Drugs and Devices Market, By Gender, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)

7. Global Infertility Drugs and Devices Market, By Region, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country, 2021 €" 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country, 2021 €" 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country, 2021 €" 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country, 2021 €" 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country, 2021 €" 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth By Type, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Gender, 2021 €" 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth By Country/Sub-region, 2021 €" 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Apricus Biosciences, Inc.*
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cristalia Produtos Quimicos Farmaceuticos Ltda.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Dong-A Pharmaceutical Co. Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Meda Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- S.K. Chemicals Co. Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Vivus, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan Pharmaceuticals Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ferring Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cipla Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Aspargo Laboratories, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Aurobindo Pharma Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lupin Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- DarA(C) Bioscience, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Torrent Pharmaceuticals Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alembic Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Reddys Laboratories Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies